Tyra Biosciences reports Q3 EPS (49c), consensus (35c)

As of September 30, TYRA had cash and cash equivalents of $215.7M that are expected to support TYRA’s important clinical and operational milestones over at least the next two years. “From the start, TYRA has focused on developing precision therapies that target large opportunities that exist in FGFR biology, and we continue to follow the data. We continue to advance TYRA-300, our oral FGFR3-selective inhibitor, as we dose expand and escalate in our SURF301 oncology study and strengthen our preclinical data package in achondroplasia,” said Todd Harris, CEO of TYRA. “Before the end of the year, we expect to update our guidance on the timing and design of our planned Phase 2 study in achondroplasia and the dosing of our first patient with TYRA-200.”